These studies demonstrate the feasibility of producing parasite MIF specific inhibitors that do not impact host MIF activity, an important prospect in consideration of a disease such as leishmaniasis in which the parasite and human cytokines may have differing impacts on disease progression. The gene discussed is MIF; the disease is leishmaniasis.